X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MB-106 is a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. It is being evaluated for the treatment of autoimmune diseases.
Lead Product(s): MB-106
Therapeutic Area: Immunology Product Name: MB-106
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
MB-109 is Mustang’s designation for the treatment regimen combining MB-101 (COH-developed IL13Rα2‐targeted CAR-T cell therapy) with MB-108 (Nationwide-developed HSV-1 oncolytic virus), which is investigated for Recurrent Glioblastoma and High-Grade Astrocytoma.
Lead Product(s): MB-101,MB-108
Therapeutic Area: Oncology Product Name: MB-109
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.
Lead Product(s): MB-106
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
Under the agreement, uBriGene gains access to all of Mustang’s assets primarily relating to the manufacturing and production of cell and gene therapies, including MB-106, a first-in-class CD20-targeted autologous CAR T therapy.
Lead Product(s): MB-106
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: uBriGene
Deal Size: $11.0 million Upfront Cash: $6.0 million
Deal Type: Agreement July 31, 2023
Details:
MB-106 (CD20-targeted autologous CAR T Cell Therapy) which plays a role in the differentiation of B-cells into plasma cells for patients with follicular lymphoma.
Lead Product(s): MB-106
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Fred Hutchinson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
MB-106 (CD20-targeted autologous CAR T Cell Therapy) which plays a role in the differentiation of B-cells into plasma cells for patients with Waldenstrom macroglobulinemia.
Lead Product(s): MB-106
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Fred Hutchinson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
MB-106, first-in-class CD20-targeted, autologous CAR T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (“BNHL”) and chronic lymphocytic leukemia.
Lead Product(s): MB-106
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
The overall response for MB-106 was 96% across all dose levels and all indications. In particular, 100% complete response rates by PET scan of patients with WM (n=2) as well as of patients with B-NHL previously treated with CD19- directed CAR T cell therapy.
Lead Product(s): MB-106
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
The lentiviral vector drug substance used to transduce patients’ cells to create the MB-106, produced at Fred Hutch has been optimized as a third-generation CAR derived from a fully human antibody, and MB-106 is currently in a Phase 1/2 in patients with B-NHLs and CLL.
Lead Product(s): MB-106,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: MB-106
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2022
Details:
MB-107, Mustang’s lentiviral gene therapy for X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease, in newly diagnosed infants under the age of two.
Lead Product(s): MB-107
Therapeutic Area: Genetic Disease Product Name: MB-107
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
